Cravit Ophthalmic may be part of symptomatic management and is considered relevant for the focused therapeutic action required to address active bacterial eye infections, applied across domains where additional symptomatic support is needed to address bacterial presence.

Applied in Managing Bacterial Eye Conditions

This medication is used for the topical treatment of bacterial external ocular infections. It is commonly used across conditions presenting with acute episodes of bacterial growth, including bacterial conjunctivitis, bacterial keratitis, and other conditions involving external ocular structures. The core therapeutic focus is addressing the bacterial presence, which assists with the resolution of the infection, and helps improve the patient's day-to-day comfort.

Addressing Acute Symptoms and Discomfort

This solution helps address symptom clusters that may become intense or disruptive and interfere with daily comfort, such as excessive purulent discharge, significant eye redness, and related stinging or foreign body sensation. By targeting the infection, this treatment contributes to improved comfort during periods of heightened symptoms and helps support functional stability.

Supportive Use in Ophthalmic Procedures

In addition to treating active disease, this solution is commonly used in clinical scenarios when infection risk reduction (prophylaxis) is needed around invasive eye procedures. This application provides support that helps ease the overall symptom burden associated with post-procedural risk.

---

Quick Fact: Relevant for Symptom Domains Involving Acute Discomfort

This medication helps address symptoms related to inflammatory or irritative states, assisting with maintaining a sense of stability when symptoms are more noticeable.

Cravit Ophthalmic solution, which contains the antibiotic levofloxacin, is primarily prescribed to treat bacterial external ocular infections such as bacterial conjunctivitis and corneal ulcers.

Contraindications and Cautions

This medication is contraindicated (should not be used) in patients with a known history of hypersensitivity or allergic reactions to levofloxacin, other quinolone antibiotics (like ofloxacin or ciprofloxacin), or any inactive ingredients in the solution.

Patients should also exercise caution and discuss usage with a healthcare professional regarding specific groups and conditions:

Patient Group/Condition	Recommendation
Children under 1 year of age	Safety and effectiveness have not been established. Use is generally not recommended.
Pregnancy	Use only if the potential benefit outweighs the potential risk to the fetus, as adequate human studies are lacking.
Breastfeeding	Use with caution, as levofloxacin is presumed to be excreted in human milk.
Wearing Contact Lenses	Contact lenses should not be worn while treating an active eye infection, especially a corneal ulcer.
Prolonged Use	Extended use can lead to the overgrowth of non-susceptible organisms, including fungi, requiring a re-evaluation of treatment.

It is essential to notify your doctor of all current medications, as systemic quinolones can interact with certain other drugs, although minimal systemic absorption occurs with ophthalmic use.

Interactions with other medicines and products

The interaction profile of Levofloxacin Ophthalmic Solution (Cravit Ophthalmic) is primarily defined by the requirements for its topical administration and an informational note regarding its drug class.

Documented Topical and Systemic Interactions

The product's official prescribing information does not list any specific drug-drug or drug-food interactions for the ophthalmic route. Given the minimal systemic absorption from eye drop administration, the potential for interactions that occur in the bloodstream is considered low.

Interaction Type	Requirement/Restriction
Co-administration with other eye drops	Must be separated by a minimum of 5 minutes from other topically applied eye medications.
Systemic Drug Class Note	Systemic quinolones (the class to which levofloxacin belongs) may affect the metabolism of theophylline and caffeine, and may enhance the effects of the oral anticoagulant warfarin and its derivatives.

Interaction-Related Constraints

The only mandatory procedural constraint stated in regulatory documents is the timing requirement for concurrent use with other topical ocular products. This separation rule is intended to prevent chemical or physical interference that could dilute or wash out the medication before absorption.

Contraindications and General Cautions

No specific medicinal product combinations are contraindicated based on the interaction section of the official label. Patients are advised that the information related to systemic interactions of quinolones is provided for context, though it does not imply that these interactions are expected with the ophthalmic solution.

Levofloxacin exerts its action through a dual-target mechanism that directly leads to the elimination of susceptible bacteria and cessation of the microbial stimulus.

Dual-Enzyme Blockade of Bacterial DNA

This mechanism engages two critical bacterial enzymes: DNA Gyrase (Topoisomerase II) and Topoisomerase IV. Levofloxacin acts as an inhibitor by binding to these enzymes and stabilizing them in a complex with cleaved DNA. This molecular action prevents the necessary re-sealing of the bacterial DNA, directly causing irreversible double-strand breaks and initiating a sequence that leads to cell death.

---

Termination of Microbial Replication and Division

The result of the dual enzyme inhibition is a forceful termination of the bacterial life cycle. By preventing the essential processes of DNA maintenance and chromosome separation (decatenation), the drug exerts a bactericidal effect (the killing of the infectious organism). This direct, lethal action on the pathogen population is the key physiological event that removes the microbial cause of inflammation, allowing the cessation of pathogen-driven tissue disturbance.

---

️ Indirect Cessation of Pathogen-Driven Inflammation

The clearance of the live bacterial inoculum from the ocular surface removes the continuous primary microbial stimulus that triggers and sustains the host’s localized inflammatory and immune responses. This mechanism results in the elimination of the source of inflammatory mediators, rather than by directly modulating human cellular pathways.

How to Use Cravit Ophthalmic — Administration Guidelines

This section describes the standard administration of Levofloxacin 0.5% ophthalmic solution. The use of this medicine is defined by a tiered, time-bound protocol for topical application.

Category	Instructions
Route of administration	The route is strictly Topical Ocular Use, which involves instilling the solution directly onto the outer surface of the eye.
Dosing schedule	Administration follows a tiered pattern of one to two drops per application. Initial treatment requires a higher frequency that is subsequently reduced to a maintenance frequency.
Frequency and Schedule	Days 1–2: Instillation is performed every 2 hours while awake, up to a maximum of 8 times per day. Days 3 through 7: The frequency is reduced to every 4 hours while awake, up to 4 times per day. A 7-day regimen is commonly utilized.
Age-group administration rules	The standard posology is the same for adults and children 1 year of age and older. No dosage adjustment is required for older adult patients.
Missed-dose rules	If a scheduled dose is missed, it should be applied as soon as remembered. However, a double dose must not be used to compensate for the skipped application.
Special procedural conditions	The solution must not be injected into the sub-conjunctival space or introduced directly into the anterior chamber of the eye. If other topical eye medications are used concurrently, a minimum of 15 minutes must elapse between the applications of the different products.
Course duration	The usual total treatment course is a fixed duration, typically either 5 or 7 days.

Cravit Ophthalmic solution contains levofloxacin, a fluoroquinolone antibacterial agent. Research into its use focuses on its application for treating various external ocular infections and its role in perioperative disinfection. The available clinical evidence generally relates to the 0.5% and 1.5% concentrations of levofloxacin ophthalmic solution.

Evidence for External Ocular Infections

Clinical trials and post-marketing surveillance data suggest that levofloxacin ophthalmic solution provides a beneficial microbial response in patients with bacterial eye infections, including conjunctivitis and keratitis. A key finding in randomized controlled trials is the ability of the solution to achieve a high rate of microbial eradication, which is the clearance of the causative bacteria from the infection site.

• Bacterial Conjunctivitis (0.5% concentration): Studies suggest that microbial eradication rates are high for susceptible organisms, ranging from approximately 89% to 92.7% across different trials. This includes activity against common pathogens such as Staphylococcus aureus and Haemophilus influenzae. In comparative studies, the microbial eradication rate for levofloxacin 0.5% was observed to be statistically higher than that of ofloxacin 0.3% at the study end point, although clinical cure rates were often reported as similar between the two groups.

• Corneal Ulcers (1.5% concentration): The higher concentration solution is studied for its use in treating bacterial corneal ulcers, which are more severe infections. Clinical findings report high microbial eradication rates for susceptible isolates in these cases. Studies have also investigated simplified dosing regimens, with some research suggesting that less frequent dosing may achieve comparable clinical cure and eradication rates to more intensive regimens, potentially improving patient compliance.

Safety and Tolerability

Across multiple large-scale post-marketing surveillance studies, levofloxacin ophthalmic solution has been generally reported as well tolerated. The incidence of adverse drug reactions is reported to be low (around 0.63% in one large surveillance study). The most commonly observed adverse events in clinical trials often include transient ocular burning or pain, decreased vision, and headache, typically occurring in 1% to 3% of patients. Prolonged use may be associated with the overgrowth of non-susceptible organisms, a consideration for all topical anti-infectives.

Common questions about Cravit Ophthalmic (FAQ)

---

Q: What is Cravit Ophthalmic Solution used for?

A: Cravit Ophthalmic Solution is an antibiotic eye drop containing the active ingredient levofloxacin, which belongs to a class of antibiotics called fluoroquinolones. It is indicated for the topical treatment of certain bacterial infections of the eye, such as bacterial conjunctivitis (pink eye) and corneal ulcers, that are caused by susceptible organisms. Its use is limited to infections where the bacteria are known or suspected to be sensitive to the medication.

---

Q: How does Cravit Ophthalmic work?

A: Cravit Ophthalmic Solution contains levofloxacin, an antibiotic that functions by interfering with the essential process of DNA replication in susceptible bacteria. This action is understood to disrupt the bacteria's ability to multiply and repair, which helps the body's natural processes address the infection.

---

Q: What are the common side effects of Cravit Ophthalmic?

A: Clinical study findings have reported that Cravit Ophthalmic may be associated with certain ocular (eye-related) side effects, as well as some systemic effects. The most commonly observed effects include:

• Temporary burning or stinging sensation in the eye upon administration.
• Eye pain or discomfort.
• Feeling like there is a foreign body in the eye.
• Temporary decreased vision or blurred vision.
• Headache.

Less frequently, other effects such as sensitivity to light (photophobia), fever, sore throat, or eyelid swelling have been observed. If severe or concerning symptoms occur, seeking guidance from a healthcare professional is advised.

---

Q: Can Cravit Ophthalmic be used by children?

A: Cravit Ophthalmic Solution is generally indicated for use in adults and children one year of age and older for the treatment of bacterial conjunctivitis. Use in infants younger than one year of age is not typically recommended. The appropriateness of the medication for a child's specific condition and age should be determined by a qualified healthcare professional.

---

Q: Is Cravit Ophthalmic safe to use during pregnancy or while breastfeeding?

A: Limited data is available regarding the use of Cravit Ophthalmic Solution during pregnancy. It is important to discuss the potential benefits and any potential risks with a healthcare provider. Regarding breastfeeding, levofloxacin may be excreted in human milk; however, the extent to which the ophthalmic dose may affect a breastfed infant is not fully established. A healthcare professional is best suited to assess the situation and provide appropriate guidance.

How to Store and Dispose of Cravit Ophthalmic?

Cravit Ophthalmic (levofloxacin ophthalmic solution) must be stored and handled according to specific regulatory requirements to ensure stability and safety.

---

Official Storage Requirements

Requirement	Specification
Temperature	Store at 20 C to 25 C (68 F to 77 F); do not freeze.
Environmental	Keep the container in the original carton to protect from light and moisture.
Child Safety	Keep this medicine out of the sight and reach of children.

---

Stability and Disposal

Stability after opening: The solution must be discarded 28 days after the first opening, even if some medicine remains.

Disposal instructions: Safely dispose of any unused, expired, or opened medicine (after the 28-day period) by following local government requirements for unused pharmaceuticals. Do not dispose of the medicine in household trash or wastewater.